Version Date: [ADDRESS_427693] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 1 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427694]  2021  
  
A randomized, blinded study of fluorescence detection of pediatric primary central nervous 
system tumors in subjects receiving tozuleristide and imaged with the Canvas System  
 
Protocol #: BB-006 
(PNOC012) 
Version Number: 5.0 
 
 
Version Date:  October 28, 2021 
IND: 122229 
     
 
    
 
    
 
 
CONFIDENTIALITY STAT EMENT  
This document contains confidential information of Blaze Bioscience (“Blaze Bioscience”).  
The information contained in this document, particularly unpublished data, is the property of or under the control of Blaze Bioscience and is provided to you in confidence as an investigator, potential investigator, or consultant, for 
review by [CONTACT_10825], your staff, and an applicable Institutional Review Board/Human Research Ethics Committee.  
The information is only to be used by [CONTACT_344502].  
Disclosure of any of the information to others requires written authorization from Blaze Bioscience  except to the 
extent necessary to obtain informed consent from those persons to whom the investigational product(s) may be administered.
 
Version Date: [ADDRESS_427695] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 2 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427696]  2021 Study Chair  
Sarah Leary, MD MS  
Seattle Children’s Hospi[INVESTIGATOR_344484]- Chair  
 
 
 
 
 
 
  Project Leader  
  
  
 
 
 
 
 
 
Co-Chair  
 
 
 
 
 
 Project Co -Leader  
 
  
 
 
 
 
Coordinating Center  
 
 
 
 
 
 
  
Revision History  
Version 1.0   
Version 1.1   
Version 2.0   
Version 3.0   
Version 4.0   
Version 5.0  
 

Version Date: [ADDRESS_427697] 2021  BB-006 (PNOC012)  
Confidential Page 3 of 95 BB-006 (PNOC012)  
Versi on Date: [ADDRESS_427698]  2021 Participating  Institutions  
Participating  Institutions 
Children’s Hospi[INVESTIGATOR_157963]  
[ADDRESS_427699] 
Detroit, MI [ZIP_CODE]  Children’s Hospi[INVESTIGATOR_7723]  
[ADDRESS_427700]., Mail Stop #54  
Los Angeles, CA [ZIP_CODE]  Children’s Minnesota  
Jim and Colleen Ryan Pediatric Cancer and Blood 
Disorders Center  
[ADDRESS_427701] South 
Minneapolis, MN [ZIP_CODE]  
Children’s National Medical Center  
Department of Neurology  
[ADDRESS_427702] NW  
Washington, DC [ZIP_CODE]  Johns Hopkins Hospi[INVESTIGATOR_344485]-800; [ADDRESS_427703].  
Baltimore, MD [ZIP_CODE]  
Seattle Children’s Hospi[INVESTIGATOR_344486]  
[ADDRESS_427704]. Jude Children’s Research Hospi[INVESTIGATOR_344487]  
[ADDRESS_427705]. Louis Children’s Hospi[INVESTIGATOR_344488]. Louis  
 One Children’s Place, 4S10  
St. Louis, MO [ZIP_CODE]  UCSF Benioff Children’s Hospi[INVESTIGATOR_344489], San Francisco  
Pediatric Brain Center  
Ron Conway Family Gateway Medical Building 
[ADDRESS_427706], 6th Floor  
San Francisco, CA [ZIP_CODE]  
University of [LOCATION_012]  
UF Health Shands Hospi[INVESTIGATOR_307]/Shands Children’s 
Hospi[INVESTIGATOR_307]  
[ADDRESS_427707], Gainesville, [LOCATION_012]  
[ZIP_CODE]  [LOCATION_007] Children’s Cancer  
and Hematology Centers 
[ADDRESS_427708]  
Houston, TX [ZIP_CODE]  

Version Date: [ADDRESS_427709] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 4 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427710]  2021  
PROTOCOL SIGNATURE [CONTACT_344536].:    BB-006 (PNOC012) Amendment 5.0 Version Date:   [ADDRESS_427711] read and understood the protocol entitled: “A randomized, blinded study of fluorescence 
detection of pediatric primary central nervous system tumors in subjects receiving tozuleristide 
and imaged with the Canvas System” 
I will conduct this study in accordance with this protocol (subject to amendments) and the current principles of Good Clinic al Practice (GCP) , International Conference on Harmonization 
(ICH  E6R2 ) guidelines 
and any additional local guidelines as applicable. Any changes in 
procedure will only be made if necessary to protect the safety, rights or welfare of subjects. I will make all reasonable efforts to complete the study within the time designated. I agree to disclose the financial interests of all investigators or sub -investigators who are directly involved 
in the treatment or evaluation of research subjects.  
This study will s upport an FDA submission and is subject to compliance with 21 CFR 312.60 
for the drug component and ISO [ZIP_CODE]:2011, [ADDRESS_427712](s) and the study  
 
 
   
Principal Investigator’s Name (Printed)   Signature  
   
  [CONTACT_1782] (dd mmm yyyy)  
Version Date: [ADDRESS_427713] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 5 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427714] OF ABBREVIATIONS  .................................................................................................. 18  
1 OBJECTIVES  .......................................................................................................... 21  
1.1 Primary Objectives  .................................................................................................... 21  
1.2 Secondary Objectives  ................................................................................................ 21  
1.3 Exploratory Objectives  .............................................................................................. 21  
2 BACKGROUND  ...................................................................................................... 22  
2.1 Study Disease ............................................................................................................ 22  
2.2 Study Agent and Device ............................................................................................ 24  
2.3 Nonclinical Studies  .................................................................................................... 25  
2.3.1  Safety summary: Tozuleristide  ..................................................................................... 25  
[IP_ADDRESS]  Serious Adverse Events  ............................................................................................. 26  
2.4 Clinical Studies  .......................................................................................................... 27  
2.4.1  Overvi ew of Clinical Studies  ....................................................................................... 27  
  
  
  
  
  
2.5 Rationale .................................................................................................................... 38  
2.5.1  Study Rationale ............................................................................................................ 38  
2.5.2  Dose R ationale  ............................................................................................................. 39  
2.5.3  Device Rationale  .......................................................................................................... 39  
  
  
  
  
  
  
  
  
3 STUDY DESIGN ..................................................................................................... 43  
3.1 Characteristics  ........................................................................................................... 43  
3.2 Number of Subjects ................................................................................................... 43  
3.3 Inclusion Criteria  ....................................................................................................... 43  
3.4 Exclus ion Criteria  ...................................................................................................... 44  
4 REGISTRATION PROCEDURES  ....................................................................... 46  
4.1 General Guidelines .................................................................................................... 46  
4.1.1  Treatment Allocation  .................................................................................................... 46  
4.1.2  Blinding ........................................................................................................................ 46  
4.1.3  Re-treatment ................................................................................................................. 46  

Version Date: [ADDRESS_427715] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 6 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427716] .............................................................................................. 47  
5.2 Imaging Device ......................................................................................................... 47  
5.2.1  Canvas System Data ..................................................................................................... 50  
5.3 Regimen Description  ................................................................................................. 51  
5.4 Phase 0/1 Dose Escalation Scheme  ........................................................................... 52  
5.5 Phase 0/1 Definition of Dose -Limiting Toxicity  ...................................................... 52  
5.6 General Concomitant Medication and Supportive Care Guidelines ......................... 52  
5.6.1  Special Dietary Requirements  ...................................................................................... 52  
5.6.2  Concurrent Medications / Treatments Not Permitted  ................................................... 52  
[IP_ADDRESS]  Prior to Study Entry .................................................................................................. 52  
[IP_ADDRESS]  On Study .................................................................................................................... 52  
5.7 Dosing Modifications and Delays ............................................................................. 53  
5.7.1  Criteria for dose -modification in case of suspected tozuleristide toxicity  and re-
initiation of treatment ................................................................................................... 53  
6 TREATMENT PLAN  ............................................................................................. 54  
6.1 Study Calendar .......................................................................................................... 54  
6.2 Observations and Procedures  .................................................................................... 56  
6.2.1  Informed Consent  ......................................................................................................... 56  
6.2.2  Screening Period (Day -14 to day of surgery) .............................................................. 56  
6.2.3  1 to 36 Hours Pre-Surgery ............................................................................................ 58  
6.2.4  Day 1 (Day of Surgery) ................................................................................................ 58  
6.2.5  Day 8 ([ADDRESS_427717]-Surgery ± 3 days) ......................................................................... [ADDRESS_427718]-Surgery (±7 days) ................................................................................... [ADDRESS_427719]-Surgery (±7 days) and [ADDRESS_427720]-Surgery (±7 days) .................... 62  
6.3 Off-Treatment Criteria ............................................................................................... 63  
6.4 Off Study Criteria  ...................................................................................................... 63  
7 ADVERSE EVENTS  ............................................................................................... 64  
7.1 Adverse Event Characteristics  ................................................................................... 64  
7.1.1  Serious Adverse Events  ................................................................................................ 65  
[IP_ADDRESS]  Clarification of Serious Adverse Events  .................................................................... 66  
7.1.2  Life-threatening  ............................................................................................................ 66  
7.2 Adverse Event Reporting .......................................................................................... 66  
7.3 SAEs and Expedited Reporting ................................................................................. 67  
7.4 Toxicity Management  ................................................................................................ 67  
7.4.1  Definitions  .................................................................................................................... 67  
7.4.2  Guidance for Dose Modification or Discontinuation of Treatment ............................. 68  
7.4.3  Warnings and Precautions ............................................................................................ 68  
8 SPECIAL STUDIES  ........................... 69  
8.1 ..................................................................................................... 69  
8.2 Investigational Device Information ........................................................................... 69  
8.3  .................................................................................................... 69  
9 EVALUATION CRITERIA  ................................................................................... 70  
9.1 Independent Safety Monitoring Committee (SMC) .................................................. 70  
9.2 Central Radiology ...................................................................................................... 70  
9.3 Central Pathology  ...................................................................................................... 70  

Version Date: [ADDRESS_427721] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 7 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427722]  2021   
9.5 Protocol Endpoint Assessment Committee (PEAC) ................................................. 71  
10 STATISTICAL CONSIDER ATIONS  ................................................................... 72  
10.1  Study Design/Endpoints ............................................................................................ [ADDRESS_427723] Exposure ............................................................................................... 77  
10.2.8  Safety Analyses  ............................................................................................................ 78  
[IP_ADDRESS]  Adverse Events  .......................................................................................................... 78  
[IP_ADDRESS]  Clinical Laboratory Parameters, ECG and Vital Signs ............................................ 78  
  
  
 
  
10.2.12  Interim Analysis  ........................................................................................................... 79  
10.3  Sample Size  ............................................................................................................... 79  
10.4  Stratification Factors  ................................................................................................. 80  
11 DATA REPORTING / REGULATORY REQUIREMENTS  ............................. [ADDRESS_427724] Records ............................................ 84  
11.3.8  Publication of Data and Protection of Trade Secrets.................................................... 84  
REFERENCES  ......................................................................................................................... 86  
APPENDIX A: PERFORMANCE STATUS CRITERIA  .................................................... 88  
  
 
 

Version Date: [ADDRESS_427725] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 8 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427726]  2021  
 
 
 
 
TABLE OF TABLES  
Table 1  Survival in children with brain tumors according to extent of tumor resection
 ................................................................................................................................... 23  
  
  
Table 4  Clinical studies  with tozuleristide  .......................................................................... 27  
 
 
  
 
  
 
  
Table 9  CTCAE Grading Scale  ............................................................................................ 65  
 
TABLE OF FIGURES  
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 

Version Date: [ADDRESS_427727] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 9 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427728] population Subjects >1 month and ≤[ADDRESS_427729] an MRI obtained within 30 days of study enrollment documenting a measurable lesion consistent with a pediatric primary CNS tumor for which maxi mal safe resection is 
indicated. 
Rationale for Study There is an urgent unmet need for a tumor-targeted imaging agent to enable real -time intraoperative distinction between malignant and 
normal tissue to improve n eurosurgical outcomes,  
 
Primary  Objective  The primary objectives of this study in subjects undergoing neurosurgical resection of pediatric primary central nervous system (CNS) tumors are : 
• To compare the sensitivity of tozuleristide and the Canvas near 
infrared (NIR) imaging system fluorescence to the sensi tivity 
of surgical designation in equivocal tissue in situ; 
• To compare the specificity  of tozuleristide and the Canvas 
system fluorescence to the specif icity of surgical designation in 
equivocal tissue in situ; 
• To evaluate imaging efficacy as measured by [CONTACT_344503];  
• To evaluate imaging efficacy as measured by [CONTACT_344504] i n equivocal tissue in situ.  
Secondary/Exploratory 
Objectives  The secondary objectives of this study are: 
• To evaluate the safety of tozuleristide administration and Canvas NIR imaging system during surgical resection of pediatric primary CNS tumors  
•  
 
 
 
  
  

Version Date: [ADDRESS_427730] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 10 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427731]  2021  
The exploratory objectives of this study will evaluate the: 
•  
  
  
 
 
Study Design  Randomized, blinded ( central pathology, central  fluorescence 
assessment  and central radiology ), multi -center study of a single dose 
of tozuleristide in subjects with pediatric primary CNS tumors; 
intraoperative imaging will be performed with the Canvas system .  
Two Arms (randomized 1:10): 
• Arm 1 (no drug treatment): ~9% of subjects   
Subject not injected with tozuleristide  and undergoes standard 
of care neurosurgery  
• Arm 2 (tozuleristide treated): ~91% of subjects  
Subject injected with tozuleristide and undergoes standard of 
care neurosurgery   
During the surgical procedure, and once the tumor has been accessed, the Canvas system, which is attached to the surgical microscope, will be used to capture and display intraoperative in situ  images (white 
light and fluorescence) of the region from which surgical specimens for biopsy or excision will be collected. All clinical decision- making 
regarding tissue resection will be made based on the routine neurosurgical practices, and tissue resection will take place under normal light conditions in line with best clinical practices.  
In addition to primary tumor biopsy, regions of equivocal na ture 
(uncertain if tumor or not tumor) will be identified before fluorescence in the operating room is determined. Each clinical site will have an imaging operator who is not operating nor involved with patient surgical management. The imaging operator will ensure white light and fluorescent images are captured and will assess and document fluorescence status (none, weak, or strong) by [CONTACT_344505]. The operating surgeon will assign presumed status of equivocal tissue (tumor/not tumor) and indicate the region to be biopsied and imaged by [CONTACT_344506].   
 

Version Date: [ADDRESS_427732] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 11 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427733] in the brain/spin e 
is noted to be fluorescent, it is always the surgeon’s decision whether to biopsy/resect if safe to do so . 
A 1:10 randomization scheme will be used to help reduce selection bias, and aid in the integrity of the blinded pathology,  
 and radiology assessments.  Subjects will be randomly 
assigned to either Arm 1 (no tozuleristide treatment) or Arm 2 
(tozuleristide  treated ) after enrollment.
 
 
 
 
 
 
 
 
 
 
  
 
Fluorescence 
assessment  by [CONTACT_344507].  
Subjects who are randomized to Arm [ADDRESS_427734] meet all study eligibility requirements and re -consent for study prior to 
re-enrollment for open- label treatment with  tozuleristide (re -
treatment).  
The pathology assessment of tissue as tumor or not tumor, for both arms, will be done by a centralized and independent panel of pathologists without knowledge of fluorescence status or treatment arm (blinded pathology). 
Post-operative centralized and independent MR image assessment  
, for both arms, will be done without knowledge of 
fluorescence status, treatment assignment, or surgical assessment 
(blinded radiology). 
 

Version Date: [ADDRESS_427735] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 12 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427736]  2021  
 
 
Number of Subjects Approximately 114 subjects are planned . 
Duration of Therapy For subjects in Arm 2, t ozuleristide will be administered as a single 
intravenous (IV) bolus dose at least one hour and no more than [ADDRESS_427737]- surgery  
Duration of study Approximately 52 months 
Study Drug(s)  
 
 
 
 
Safety Assessments All adverse events (AEs) and SAEs for up to three  months after 
surgery will be recorded and graded for evaluable subjects according to the National Cancer Institute’s Common Terminology for Adverse Events (NCI CTCAE, Version 5.0) along with attribution of relatedness to tozuleristide and/or Canvas system an d neurosurgery 
(related vs. unrelate d). After the Day 8 visit, all subjects will be 
followed by [CONTACT_22263]/or telephone contact [CONTACT_344508], or until an off- study criterion is met, to collect survival, 
toxicity assessment , and disease st atus information.  
Any subject receiving additional therapy for their CNS tumor, including chemotherapy and/or radiation therapy within three  months 
of surgery will be considered off study for safety observations at the time of  starting additional therapy. Safety data in these subjects will be 
included up to the time the subject begins additional tumor- directed 
therapy. Quality of life assessments will be collected in all subjects through three  months post-surgery. 
Primary endpoints Primary efficacy endpoints are:  
1. Ratio of sensitivity of tozuleristide fluorescence in equivocal tissue biopsies from subjects with fluorescence- positive tumors 
compared to the sensitivity of surgical designation from the same biopsies under white light conditions 
2. Ratio of specifi city of tozuleristide fluorescence in equivocal 
tissue biopsies from subjects with fluorescence- positive tumors 
compared to the specificity of surgical designation from the same biopsies under white light conditions 

Version Date: [ADDRESS_427738] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 13 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427739] tumor in 
equivocal tissue biopsies from subjects with fluorescence -
positive tumor 
Tozuleristide fluorescence is determined by [CONTACT_344509].  
 
 
  
 
 
Secondary endpoints Secondary efficacy endpoints are: 
1.  
 
2. 
 
 
 
 
 
 
  
Secondary endpoints related to the safety objective: 
1. All reported adverse eve nts (AEs)  will be graded according to 
the National Cancer Institute’s Common. Terminology for Adverse Events (NCI CTCAE, Version 5.0) 
2. SAEs  
3. AE attribution of relatedness to tozuleristide  and/or Canvas 
system (related vs. unrelated).  

Version Date: [ADDRESS_427740] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 14 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427741]  2021 4. Laboratory parameters  
5. ECG parameters  
6. Vital signs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
  

Version Date: [ADDRESS_427742] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 15 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427743]  2021  
  
 
Other study endpoints   
  
  
 
  
  
  
 
 
  
  
  
  
 
 
Sample size 
determination  The sample size is based on the four co -primary endpoints for the 
tozuleristide arm (Arm 2). 
The sample size for the ratio of sensitivity of tozuleristide fluorescence in biopsies compared to the sensitivity of surgical designation from the same biopsies under white light conditions is based on the equivocal tissue biopsies from the subjects with fluorescence-positive tumor assessed for fluorescence and standard of care/white light conditions. 
 
 
 
  
  
 

Version Date: [ADDRESS_427744] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 16 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427745]  2021  
 
 
The sample size for sensitivity and specificity of tozuleristide 
fluorescence is based on the equivocal tissue biopsies from the subjects 
with fluorescence-positive tumor.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unique Aspects of this 
Study This is a novel and rapi[INVESTIGATOR_344490]. 
 

Version Date: [ADDRESS_427746] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 17 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427747]  2021 EXPERIMENTIAL DESIGN SCHEMA 
 
  Figure 1  
 
 
 

Version Date: [ADDRESS_427748] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 18 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427749] measurable time point  
BSA  body surface area  
BUN  blood urea nitrogen 
cGMP  current good manufacturing principles 
CI confidence interval(s) 
CL total body clearance 
Cmax maximum observed concentration  
CNS  central nervous system  
C0 concentration back- extrapolated to time [ADDRESS_427750] visit  
GCP  good clinical practice  
GEE  general estimating equation  
GFAP  glial fibrillary acidic protein  
GLP  good laboratory practice(s)  
GTR  gross total resection  
H&E  hematoxylin and eosin 
HDD  hard-disk drive 
Version Date: [ADDRESS_427751] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 19 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427752] 
ISF investigator site file  
IV Intravenous 
LC/MS  liquid chromatography / mass spectrometry 
LLOQ  lower limit of quantitation  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  magnetic resonance i maging 
NCI National Cancer Institute  
NHP  nonhuman primate 
NIR near infrared  
NOAEL  no-observed-adverse- effect -level  
NPV  negative predictive value 
NTR  near total resection  
OS overall survival 
PEAC  Protocol Endpoint Assessment Committee  
PFS progression- free survival  
PK pharmacokinetic(s) 
PPV positive predictive value  
ROI region of interest 
SAE  serious adverse event  
SAP statistical analysis plan  
SD standard deviation 
SIRIS  Synchronized Infrared Imaging System 
SMC  Safety Monitoring Committee 
SOC  standard of care  
SOP standard operating procedure 
Version Date: [ADDRESS_427753] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 20 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427754]  2021 STR subtotal resection  
T Time 
TK Toxicokinetic 
Tmax time of maximum observed concentration 
TN true negative 
TP true positive 
t1/[ADDRESS_427755]  upper limit of normal 
V Volume  
Vss apparent volume of distribution at steady -state 
WHO  World Health Organization 
 
Version Date: [ADDRESS_427756] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 21 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427757]  2021 1 OBJECTIVES  
1.1 Primary Objectives  
The primary objectives of this study in subjects undergoing neurosurgical resection of pediatric 
primary CNS tumors are: 
• To compare the sensitivity of tozuleristide and the Canvas near infrared (NIR) imaging 
system fluorescence to the sensit ivity of surgical designation in equivocal tissue in situ 
• To compare the specificity of tozuleristide and the Canvas system fluorescence to the specif icity of surgical designation in  equivocal tissue in situ 
• To evaluate imaging efficacy as measured by [CONTACT_344503]  
• To evaluate imaging efficacy as measured by [CONTACT_344510]. 
1.2 Secondary Objectives  
The second ary objectives of this study are: 
•  
 
  
 
  
  
1.3 Exploratory Objectives 
The exploratory objectives of this study will evaluate the: 
•
 
  
 
  
 
 

Version Date: [ADDRESS_427758] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 22 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427759]  2021 2 BACKGROUND  
2.1 Study Disease  
Brain tumors are the leading cause of cancer death in children. Neurosurgical resection of gross 
disease remains an essential component of care and cure for the majority of pediatric brain tumors, including high-grade glioma ( Yang 2013), ependymoma ( Pollack 1995, Rogers 2005), 
medulloblastoma ( Zeltzer 1999), supratentorial primitive neuroectodermal tumor (Jakacki 2015) 
and atypi[INVESTIGATOR_344491]/rhabdoid tumor ( Chi 2009) as detailed in Table 1  below. Low-grade 
gliomas may be cured with surgery alone ( Fisher 2008). Survival of patients with both low- and 
high- grade gliomas is enhanced with maximal tumor resection ( Hervey -Jumper 2015). 
 
Version Date: [ADDRESS_427760] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 23 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427761]  2021 Table 1 Survival in children with brain tumors according to extent of tumor resection  
 
Tumor histology  Survival 
measure-
ment time  Survival for 
children with 
complete 
resection  Survival for 
children 
with 
residual 
disease  P value  Estimated 
GTR rate  Reference  
Glioblastoma  5-year OS  42% (n=17)  0% (n=20)  NA ~45%  Yang, 2013  
Ependymoma  5-year OS  80% (n=23)  22% (n=14)  < 0.0001  ~60%  Pollack, 
1995 
Supratentorial 
primitive 
neuroectodermal 
tumor  5-year OS  
(stage M0 
tumor) 59% (n=1 7) 10% (n=12)     0.017  ~60%  Jakacki, 
2015 
Medulloblastoma  5-year PFS  
(stage M0 
tumor and 
≥3 years 
age) 78% (n= 61, 
includes 
patients with 
<1.5cm2 
residual tumor ) 54% (n= 22, 
includes 
patients 
with 
≥1.5cm2 
residual 
tumor )    0.023  ~75%  
(NTR+GTR)  Zeltzer, 
1999 
Atypi[INVESTIGATOR_344492]/rhabdoid tumor  2-year OS 91% (n=11)  NA    0.004  ~55%  Chi, 2009  
Low grade glioma  5-year PFS  90% (n=52)  36-48% 
(n=213) <0.001  ~20%  Fisher, 2008  
OS: overall survival; PFS: progression -free survival ; GTR: gross total resection; M0: no evidence of metastasis  
Even the most experienced neurosurgeons are challenged by [CONTACT_344511]. 5 -aminolevulinic acid (ALA) is an intraoperative imaging agent 
that was developed and approved for clinical use in Europe for adults with glioblastoma. In a randomized controlled trial of adults with glioblastoma, ALA was significantly more likely to result in gross total resection, with 65% in the ALA group achieving gross total resection compared to 36% in the control group (p<0.05). In addition, the ALA group achieved a significantly (p<0.05) greater 6 -month survival of 41% compared to 21% in the control arm 
(Stummer 2006). The study of ALA in adults with glioblastoma demonstrates that intra operative 
imaging may have a greater impac t on patient survival (20% difference) than any medical 
therapy developed to date, including temozolomide which resulted in 15% improvement in survival in the initial landmark study leading to [LOCATION_002] Food and Drug Administration 
(FDA) approval ( Stupp 2005). A recent systematic review and meta-analysis concluded that the 
intraoperative imaging agent ALA was superior to neuronavigation for adults with high grade glioma, resulting in improved extent of resection, survival, and quality of life ( Zhao 2013). 
However, ALA is not likely to be applicable to pediatric use. Several reports of off -label use of 
ALA in children in Europe have decreased enthusiasm for developi[INVESTIGATOR_344493], most significant of which is the limited or lac k of binding to the most common 
pediatric histologic types of brain tumors, low-grade lesions and embryonal tumors such as medulloblastoma ( Barbagallo 2014, Beez 2014). Furthermore, ALA does not bind to brain tumor 
cells, but instead localizes based on blo od brain barrier disruption, leading to potential false-
positive and false-negative signals. 
Version Date: [ADDRESS_427762] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 24 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427763]  2021 Tozuleristide ( also known as BLZ -100) is a targeted fluorescent molecule designed by [CONTACT_344512]. T he peptide component of 
tozuleristide  
 
 
 
 
 
The fluorophore component of tozuleristide is a conjugatable form of indocyanine green ( ICG). 
ICG is a cyanine dye that has been approved by [CONTACT_344513] 1950s. Following excitation, i t has an emission wavelength higher than 
800 nm which is minimally absorbed by [CONTACT_344514], making it well- suited for 
intraoperative imaging w hen used with an appropriate detection device. ICG is frequently 
employed in vascular and ophthalmology surgery as well as for sentinel lymph node mappi[INVESTIGATOR_007]. 
Visualization of the near infrared (NIR) fluorescence from ICG is accomplished using an imaging system, typi[INVESTIGATOR_344494] a light source for excitation, a camera to detect NIR fluorescence and a monitor to display the images from the camera. Commercially available NIR imaging systems for ICG detection, such as the Fluobeam® 800 (Fluoptics) imaging system or the Artemis Handheld Imaging System/Spe ctrum (Quest Medical Imaging),  
 
 
 
 
 
 
Preclinical data show that chlorotoxin-based dye conjugates bind specifically to a range of human and animal tumors and provide greatly improved image resolution compared with pre -
operative magnetic resonance imaging (MRI) or direct intraoperative observation, and greater imaging time window flexibility. Thus, they may enable surgeons to visualize and remove tumor cells that would otherwise have remained undetected and more precisely view tumor margins, resulting in more complete surgical resection . 
2.2 Study Agent and Device  
Agent:  Tozuleristide (also known as BLZ-100) supplied by [CONTACT_344515]#  IND Sponsor  
Tozuleristide  IND:  Blaze Bioscience  
 
Investigational Device  IDE#  (see 
note below)  IDE Sponsor  
Canvas  NIR imaging system  IND:  Blaze Bioscience  

Version Date: [ADDRESS_427764] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 25 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427765]  2021  
For more information on tozuleristide, please refer to the current Investigator’s Brochure(s): 
Tozuleristide Investigator’s Brochure . 
For Device information, please refer to the current Canvas Imaging System Investigator’s 
Brochure . 
2.3 Nonclinical Studies  
All nonclinical studies are described and summarized in the Tozuleristide Investigator’s 
Brochure . 
 
 
 
 
 
 
 
  
    
     
       
       
       
     
  
2.3.1 Safety summary: Tozuleristide  
 
 
 
For the most current safety information, refer to the Tozuleristide Investigator’s Brochure .  
 
 
 
 
 
 
Overall, the clinical studies in adults and pediatrics have shown that tozuleristide appears to be 
safe and well -tolerated.  

Version Date: [ADDRESS_427766] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 26 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427767]  2021   
 
         
 
 
 
 
 
 
       
         
 
       
         
         
          
          
         
          
 
       
         
         
 
       
         
         
         
 
       
         
 
       
         
 
       
         
 
       
          
 
 
  
 
 
 
 
[IP_ADDRESS]  Serious Adverse Events 
To date, there have been no tozuleristide related serious adverse events reported. 

Version Date: [ADDRESS_427768] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 27 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427769]  2021 2.4 Clinical Studies  
2.4.1 Overview of Clinical Studies  
Table 4  provides an overview of the Phase 1  clinical studies with tozuleristide.  
Table 4 Clinical studies with tozuleristide  
Study No.  
Phase / Status  Design  
Objectives  Population  Dosage of Tozuleristide 
and Frequency  
 
BB-001  
Phase 1 / 
Complete  Open -label, FIH, dose -
escalation/expansion study  
Primary objectives: safety and tolerability  
Secondary objectives: PK, dose level for Phase 2 studies  Adult subjects with skin cancer 
undergoing 
surgical excision of their tumor(s)  21 subjects treated  
1 – 18 mg IV, single 
15 minute infusion 
48 hours prior to surgery  
 
BB-002  
Phase 1 / Complete  Open -label, dose -escalation study 
evaluating doses up to 30 mg 
Primary objectives: safety and tolerability  
Secondary objectives: PK, fluorescent 
signal from excised brain tumor tissue, 
dose level for Phase 2 studies  Adult subjects with 
glioma undergoing 
surgical excision of their tumor(s)  17 subjects treated  
3 – [ADDRESS_427770] two  hours prior to 
surgery  
 
BB-004 
Phase 1 /  
Complete  Open -label, dose -escalation and 
expansion study  
Primary objectives: safety and tolerability, PK, recommended Phase 2 dose  Pediatric subjects 
with primary CNS 
tumors   
 
 
 
BB-005 
Phase 1 / 
Complete  Open -label, exploratory study  
Primary objective: safety and tolerability  
Secondary objectives: fluorescent signal 
intensity from excised tumor tissue, PK 
in subjects with breast cancer.  Adult subjects with 
solid tumors 
(breast, lung, prostate, 
colorectal, and 
“other”) undergoing surgery  [ADDRESS_427771] two  hours prior to 
surgery  
CNS = central nervous system; FIH = first in human; IV = intravenous; PK = pharmacokinetic  
  
 
The above clinical studies are presented in detail in Tozuleristide Investigator’s Brochure . 
In the clinical studies to date, visualization of tozuleristide  has been performed using more than 
one imaging system, 
 
 
 
 
 
  

Version Date: [ADDRESS_427772] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 28 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427773]  2021  
 
 
 
 
2.4.2  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
  
  
 

Version Date: [ADDRESS_427774] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 29 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427775]  2021   
 
  
   
 
   
     
   
     
 
  
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
 
  
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
 
  
  
 
  
 
  
 
  
  
  
 
  
 
 
 
    
    
 
  
  
 
 
  
 
 

Version Date: [ADDRESS_427776] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 30 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427777]  2021  
 
2.4.3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427778] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 31 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427779]  2021  
 
 
2 1  Q nt 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[IP_ADDRESS]  
 
 
 

Version Date: [ADDRESS_427780] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 32 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427781]  2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427782] 2021  
 BB-006 (PNOC012)  
 
 
Confidential Page 33 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427783]  2021   
 
 
    
  
 
 
  
 
 
 
  
  
  
 
 
   
  
  
   
 
             
             
             
             
             
    
         
             
  
            
             
             
    
         
  
   
         
             
             
  
            
 
  
 
 
 
 
 

Version Date: [ADDRESS_427784] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 34 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427785]  2021  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427786] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 35 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427787]  2021  
 
  
 
 
 

Version Date: [ADDRESS_427788] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 36 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427789]  2021  
 
  
  
 
 
 
 
 
  
 
  
  
  
  
 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
   
 
 

Version Date: [ADDRESS_427790] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 37 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427791]  2021  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427792] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 38 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427793] common solid tumor type within the pediatric population, with about 
2,500 new cases of malignant brain tumors per year (ages 0-19) in the US ( Gajjar 2013 ). 
Furthermore, pediatric central nervous system cancer is the leading cause of cancer death in 
children (U.S. Cancer Statistics Working Group). Surgery is first- line treatment for eligible 
pediatric brain tumor patients (Sievert 2009, Robertson 2006 ). Surgical resection significantly 
affects chance of cure in the majority of pediatric CNS tumor types, including medulloblastoma, atypi[INVESTIGATOR_344491]/rhabdoid tumor, ependymoma, high-grade glioma, and low-grade glioma (Fisher 2008 ). However, surgical damage to healthy brain can lead to devastating long- term side 
effects.  
Current detectio n techniques such as intraoperative MRI, ultrasound, positron emission 
tomography scanning, and magnetoencephalography are not precise enough and do not have 

Version Date: [ADDRESS_427794] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 39 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427795]  2021 high surgical usefulness as these techniques are often not feasible during the time of surgery 
without significant disruption to the operative flow ( Huang 2013).  
While primary tumor may be readily recognized by [CONTACT_344516], there are frequently areas of equivocal tissue identified during the course of a prolonged tumor resection where the goal is maximal safe surgical resection. Equivocal tissue may be present for a number of reasons including tumor invasion into normal brain, retraction artifact, gliosis , local tissue reaction to the presence of tumor , or scar tissue from previous 
procedures. Equivocal tissue may represent marginal or ambiguous areas where the addition of neurosurgical imaging agent such as tozuleristide may provide the most utility. For this reason, this study is designed to evaluate eff icacy in these equivocal areas.  
There are few other studies in pediatric neuro -oncology that have attempted to evaluate and 
quantitate routine neurosurgical experience with areas of equivocal tissue. In this study we will therefore focus the primary efficacy analysis on an assessment of tissue fluorescence in the 
operating room (local assessment) and in addition capture and compare to the routine neurosurgical assessment of equivocal tissue planned for resection.    
There is an urgent unmet need for a tumor-targeted imaging agent to enable real- time 
intraoperative distinction between tumor and non-tumor tissue to improve neurosurgical outcomes, either as increased chance of a complete total resection or decreased risk of inadvertent normal brain resection or both. 
2.5.2 Dose Rationale 
Safety, pharmacokinetic, and imaging data from the Phase 1 clinical studies support a near -
optimal tozuleristide dose for pediatric central nervous system tumors of ~15 mg/m
[ADDRESS_427796] 1 hour before the start of surgery. 
•  
 
  
 
  
 
 
  
 
 
  
2.5.[ADDRESS_427797] features capable of detecting 

Version Date: [ADDRESS_427798] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 40 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427799] the NIR fluorescence of tozuleristide in the intraoperative setting of neurosurgery.  
 
 
 
  
 
 
 
 
 
2.5.4  
[IP_ADDRESS]  
  
[IP_ADDRESS]  R n 
  
 
 
 
 
 
[IP_ADDRESS]  
  
[IP_ADDRESS]  
  
 

Version Date: [ADDRESS_427800] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 41 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427801]  2021  
 
[IP_ADDRESS]  
 
 
 
 
 
 
 
 
[IP_ADDRESS]  R s 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427802] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 42 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427803]  2021  
 
 
 
2.6  
 
•  
  
  
  
 
  
 
    
     
 
 
  
    
    
  
 
 
  
 
  
  
 
  
  
  

Version Date: [ADDRESS_427804] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 43 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427805]  2021 3 STUDY DESIGN  
3.1 Characteristics  
This is a randomized, blinded  (central pathology, central fluorescence assessment , and central 
radiology), multi- center  Phase 2  study of a single dose of tozuleristide in subjects with pediatric 
primary CNS tumors; intraoperative imaging will be performed with the Canvas system . 
There will be 2 arms (randomized 1:10): 
• Arm 1 (no drug treatment): ~9% of subjects 
Subject not injected with tozuleristide and undergoes standard of care neurosurgery 
• Arm 2 (tozuleristide treated): ~91% of subjects  
Subject injected with tozuleristide and undergoes standard of care neurosurgery 
 In addition, re-treatment with  tozuleristide  after the initial neurosurgery may be allowed if 
additional neuro surgery is needed (Section 4.1.3 ). Data collected after re- treatment will 
constitute the re -treatment arm.  
3.[ADDRESS_427806] meet all of the following criteria to be inclu ded in this study: 
1. Subjects must be >1 month and ≤[ADDRESS_427807] MRI obtained within 30 days of study enrollment documenting a 
measurable lesion consistent with a pediatric primary CNS tumor for which maximal safe resection is indicated  
3. Adequate renal function defined as: 
a. Serum creatinine within normal limits for age or calculated creatinine clearance ≥75 mL/min/1.73 m
2 based on Schwartz equation or normal creatinine for age 
based on the following table: 
Age Maximum Serum 
Creatinine (mg/dL)  
 Male  Female  
1 to < 2 years  0.6 0.6 
2 to < 6 years  0.8 0.8 
6 to < 10 years  1 1 
10 to < 13 years  1.2 1.2 
13 to < 16 years  1.5 1.4 
≥ 16 years  1.7 1.4 
 
4. Adequate liver function defined as: 
a. Bilirubin <2 x upper limit of normal 
b. Alanine aminotransferase (ALT) < 3 x upper limit of normal 
c. Serum albumin >2 g/dL 
Version Date: [ADDRESS_427808] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 44 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427809]  2021 5. Prior therapy: Subjects with prior therapy are eligible provided they have recovered from 
any acute tox ic effects of prior therapy and have sufficient time int erval prior to 
enrollment: 
a. Radiation therapy: subjects may not have had radiation therapy to the area of tumor planned to be resected within 28 days of study enrollment 
b. Chemotherapy: at least 14 days from any myelosuppressive chemotherapy (28 days if prior nitrosourea) and if prior chemotherapy, must have an absolute 
neutrophil count recovery of ≥ 1000/mm3 following count nadir 
c. Biologic: at least seven  days from any anti- neoplastic biologic agent (at least 
three  half-lives since last administration of monoc lonal antibodies)  
d. Immunotherapy: at least 42 days after completion of any cellular immunotherapy, such as CAR -T cell therapy  
e. Prior surgery for CNS tumors is allowed  
f. Prior tozuleristide: at least one week  after prior dose of tozuleristide if previously 
treated. NOTE: Subjects previously enrolled on PNOC012 study and randomized 
to either Arm 1 (control) or Arm 2 (treatment) will be eligible for re -enrollment 
for open- label treatment of tozuleristide ( re-treatment ) in the event another 
surger (ies) is clinically indicated (Section 4.1.3 ).  
 
6. Written informed consent must be obtained from the subject or parent or legal guardian prior to the conduct of study activities. Routine clinical tests, e.g., MRI, clinical laboratory studies, may be used for screening requirements. Assent, when appropriate, will be obtained according to institutional guidelines. 
7. The risks of treatment with tozuleristide during pregnancy have not been evaluated. Female subjects of child -bearing potential must agree not to attempt to become pregnant 
or undergo in vitro  fertilization and, if participating in sexual activity that coul d lead to 
pregnancy, must use two reliable methods of contraception simultaneously for [ADDRESS_427810] agree not to attempt to father a child and, if 
participating in sexual activity that could lead to pregnancy, mus t use two  reliable 
methods of contraception simultaneously for 30 days after surgery if their partner is of child -bearing potential. (Refer to Section 6.2.2 for reliable methods of contraception). 
3.4 Exclusion Criteria  
Subjects meeting any of the following criteria will be considered ineligible for this study: 
1. Pregnancy and contraception: Subjects who are pregnant or breastfeeding or planning to conceive a child within [ADDRESS_427811]- surgery . 
2. Subjects with on-going serious medical conditions (poorly controlled asthma, diabetes, heart disease) such that participation in the study could put the subject at increased risk of worsening their condition. 
3. Subjects planned to undergo only a diagnostic biopsy procedure, without intent to resect tissue for ther apeutic purposes (e.g., stereotactic pontine biopsy). 
4. Subjects who in the opi[INVESTIGATOR_344495]-required study procedures and observations. 
Version Date: [ADDRESS_427812] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 45 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427813]  2021 Subjects previously enrolled and randomized to Arm 1 (control) are not eligible for re -
enrollment unless a second surgery is required by [CONTACT_9518].  
Important note: The eligibility criteria listed above are interpreted literally and cannot be 
waived. 
Version Date: [ADDRESS_427814] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 46 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427815] be provided for Study Chair and/or  
Project Leader review and confirmation of eligibility prior to randomization.  
4.1.1 Treatment Allocation  
After enrollment, , subjects will be 
randomized 1:10 to Arm 1 (no drug treatment ) or Arm 2 (tozuleristide treatment).  
Arm 1: Approximately ten  subjects (~9% of subjects) will not receive tozuleristide and will 
undergo standard of care neurosurgery. 
Arm 2: Approximately 104 subjects (~91% of subjects) will receive tozuleristide at a do se of 
15 mg/m
[ADDRESS_427816] one hour and no more than 36 hours 
before the planned start time of surgery. Re-treatment arm: See Section 4.1.3 below regarding re- treatment.  
4.1.2 Blinding  
This is a randomized, blinded  (central pathology, central fluorescence assessment , and central 
radiology) study. A 1:10 randomization scheme will allocate ~9% of subjects to a no study drug 
standard of care neurosurgery arm. This will help to reduce subject selection bias and expectation of fluorescence in the operating room.
 
 
The pathology assessment of tissue as tumor or not tumor, for both arms, will be done by a centralized and independent panel of two  pathologists without knowledge of fluorescence status, 
surgeon’s designation of tissue status or treatment arm (blinded pathology). 
 
 
 
Post-operative centralized MR image assessment , for both a rms, will be 
performed by a central and independent radiologist without knowledge of fluorescence status, treatment assignment  or surgical assessment (blinded radiology).  
4.1.3 Re-treatment  
Subjects who are randomized to Arm 1 (no tozuleristide) or Arm [ADDRESS_427817] meet all study eligibility requirements and re -consent for 
study prior to re-enrollment.  

Version Date: [ADDRESS_427818] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 47 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427819] one  hour (and no more than 36 hours) before the subject’ s planned 
surgical tumor excision.  
   
 
  
Tozuleristide will be given at a n IV bo lus dose of 15 mg/m2 over approximately 1-5 minutes. 
5.2 Imaging Device 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 

Version Date: [ADDRESS_427820] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 48 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427821]  2021  
 
 
 
 
 

Version Date: [ADDRESS_427822] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 49 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427823]  2021  
 
 
 
 
 
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427824] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 50 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427825]  2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
5.2.1 Canvas System Data  
For every imaging procedure, the Canvas system collects a variety of data.  

Version Date: [ADDRESS_427826] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 51 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427827]  2021  
 
 
 
 
 
5.3 Regimen Description  
Arm 1: Approximately ten  subjects.  
Subjects randomized to  standard of care neurosurgery arm (Arm 1) will not receive tozuleristide.  
  
 
 
 
  
 
 
 
 
 
 
 
 
 
All clinical decision -making regarding tissue resection should be made based on the routine 
neurosurgical practices, and tissue resection will take place under normal light conditions in line 
with best clinical practices.  
 Arm 2: Approximately [ADDRESS_427828] one hour and no more than 
36 hours before the planned start time of surgery. Tozuleristide will be given at a dose of 15 mg/m
2.  
 
 
 
 
 

Version Date: [ADDRESS_427829] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 52 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427830] is noted to be fluorescent, it is always the surgeon’s decision whether to 
biopsy/resect if safe to do so.    
5.4 Phase 0/1  Dose Escalation Scheme 
Not applicable. 
5.5 Phase 0/[ADDRESS_427831] or their legal representative about any medication taken, including vitamin supplements and herbal remedies. Any concurrent medications from Screening ( -14 days prior to surgery) until Day [ADDRESS_427832]’s records and the case report form (CRF). Any changes in doses or introduction of new medications during this period  will also be recorded . Any medications 
necessary for treatment of a SAE up to three  months post- surgery should be recorded in the 
subject’s CRF.  
5.6.1 Special Dietary Requirements  
There are no special dietary requirements.  
5.6.2 Concurrent Medications / Treatments Not Permitted  
[IP_ADDRESS]  Prior to Study Entry  
None 
[IP_ADDRESS]  On Study  
• Concurrent Anticancer Therapy Subjects may begin other appropriate anti -cancer therapy including chemotherapy and/or 
radiation therapy , but they will be considered off study for safety endpoints on the day 
when further tumor- directed therapy is initi ated.  
• Supportive Care  
No specific supportive care is recommended related to tozuleristide. Subjects should continue to receive all routine preoperative and postoperative supportive care, including 

Version Date: [ADDRESS_427833] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 53 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427834]  2021 steroids, blood products, fluids, and prophylaxis or treatment of pain, nausea, vomiting, 
seizures, or infection. Allergic reaction may occur with any medication and should be managed per institutional guidelines. 
• Pregnancy  
If a subject on study is found to be pregnant or the partner of a male subject becomes pregnant within 30 days of study drug administration, then the possible prenatal exposure to study drug should be promptly reported. 
5.7 Dosing Modifications and Delays 
No dosing modifications are expected . 
5.7.1 Criteria for dose- modification in case of suspected tozuleristide toxicity and re-
initiation of treatment  
Since tozuleris tide is given as a sing le IV bolus; no dose modifications are expected . 
 
Version Date: [ADDRESS_427835] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 54 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427836]  2021 6 TREATMENT PLAN  
6.1 Study Calendar  
. 

Version Date: [ADDRESS_427837] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 55 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427838]  2021   

Version Date: [ADDRESS_427839] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 56 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427840]  2021  
  
  
 
  
  
 
 
 
  
 
  
 
 
  
 
  
  
 
 
 
 
 
6.2 Observations and Procedures 
6.2.1 Informed Consent  
• Signed informed consent: Protocol and consent documents must be approved by [CONTACT_344517]. The investigational nature and objectives of the trial, procedures involved, potential risks and discomforts, and alternative options will be carefully explained to the subject and/or the subject’s parents or guardian, and a signed informed consent and assent, if appropriate, will be obtained according to institutional guidelines. Informed consent must be obtained prior to obtaining any study specific observations that are outside of standard clinical care in order to determine study eligibility.  
6.2.2 Screening Period (Day -14 to day of surgery) 
• Eligibility criteria: Before the subject is enrolled, a site investigator must sign and date a completed eligibility checklist verifying review and determination that the subject meets all eligibility req uirements and does not meet any exclusion criteria. These criteria and 
supporting information will be reviewed by [CONTACT_344518]-up and confirmed by [CONTACT_344519]- up prior to randomization.  
Eligibility criteria (inclusion and exclusion criteria) cannot be waived. Clinical and laboratory data to determine eligibility must be available in the subject’s medical or research record which will serve as source documentation for verification at the time of audit. 
In order to assess any potential im pact on subject eligibility with regard to safety, the 
investigator must refer to the relevant document(s) for detailed information regarding 
warnings, precautions, contraindications, AEs, and other significant data pertaining to the 

Version Date: [ADDRESS_427841] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 57 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427842] and the Canvas  system being used in this study. Such 
documents may include, but are not limited to, the Investigator’s Brochure or equivalent 
document(s) provided by [CONTACT_344520]. 
Subjects will be eligible for enrollment once all screening tests and procedures are 
completed and results indicate that all eligibility criteria have been met. Once approved, subjects will be randomized 1:10 to Arm 1 (no drug treatment, standard of care neurosurgery) or Arm 2 (tozuleristide treatment).  Subjects on re -treatment  arm will be 
assigned a new subject  number and not be subject to randomization, but still must go 
through the study eligibility and approval process. 
• Demographics 
• Medical history  
• Medication history  
• Body weight 
• Height 
• Performance status: See Appendix A  
• Physical examination 
• Concurrent medications  
• Measurement of clinical chemistry parameters: Sodium, Potassium, Chloride, CO2, blood urea nitrogen (BUN), creatinine, alanine aminotransferase (ALT), bilirubin, albumin. 
• Measurement of hematology parameters: Complete blood count (red blood cells , white 
blood cells with differential, platelets),  hemoglobin and hematocrit. 
• Measurement of coagulation parameters : PT/INR and PTT.  
• Pregnancy test ( for females of childbearing po tential): All women of child bearing 
potential (defined as sexually mature female  who has had menses within the preceding 24 
months and has not undergone hysterectomy, bilateral oophorectomy, or tubal ligation) must have a negative pregnancy test ( urine or serum  test with a sensitivity of at least 50 
IU/mL) performed at Screening/ Baseline.  
Women of childbearing potential must agree not to attempt to become pregnant or undergo in vitro  fertiliz ation and, if participating in sexual activity that could lead to 
pregnancy, must use two reliable methods of contraception simultaneously for [ADDRESS_427843] be used: 
o Condoms (male or female) with spermicide  
o Diaphragm or cervical cap  
o Intrauterine Device  
o Hormonal-based contraception 
o Vasectomy  
 
Women (including pre-pubescent females) who are not of reproductive potential are not 
Version Date: [ADDRESS_427844] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 58 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427845]  2021 required to use contraception. 
 
• MRI of tumor: MRI with and without contrast prior to treatment should be obtained 
within [ADDRESS_427846], T2, FLAIR, and Diffusion weighted images.  
For recommended 
imaging protocol and sequence parameters, please see Appendix F .  
 
 All MRI processes for central radiology will be 
detailed in the study reference manual.  
 
•  
6.2.3 1 to 36 Hours Pre- Surgery  
• ECG (Arm 2 and re- treatment arm only):  On the day of tozuleristide dosing, a baseline 
ECG will be obtained prior to dosing (within 24 hours), and an additional ECG will be obtained 1-[ADDRESS_427847] ten  minutes and will be 
measured in triplicate over approximately 3 minutes  (with wait time of approximately 
one minute between recordings) . A 12-lead ECG recording will be performed in a 
standardized manner as outlined in the Study Reference Manual. Repeat measurements will be performed if any clinical abnormalities are observed or if artifacts are present.  
• Vital signs  obtained pre -surgery (Arm 1) or pre-dose and 1-[ADDRESS_427848]-end of dose  
(Arm 2 and re- treatment arm).  
• Concurrent medications: continuous assessment  
• Adverse events: continuous assessment  
• Study drug administration (Arm 2 and re- treatment arm only): Tozuleristide is to be 
administered at least 1 hour (and no more than 36 hours) before the planned start of the surgical excision of the tumor. 
• 
 
 
 
 
 
6.2.4 Day 1 (Day of Surgery) 
• Imaging and pathology during surgery (for all subjects) 
•  
o Surgery will be conducted according to standard of care procedures, including for tumor approach and resection  
All clinical decision making 
should be made based on routine neurosurgical practices and tissue resection will 

Version Date: [ADDRESS_427849] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 59 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427850] clinical practice  
o  
 
o  
 
 
 
   
  
 
 
 
 
  
 
 
 
 
 
 
1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427851] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 60 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427852]  2021  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
1.  
 
 
 
 
 
 
 
  
 
 
  
 
 
 

Version Date: [ADDRESS_427853] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 61 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427854]  2021 7.  
 
 
 
 
 
o  
 
 
  
 
 
  
• Concurrent medications: continuous assessment  
• Adverse events: continuous as sessment  

Version Date: [ADDRESS_427855] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 62 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427856]  2021 • MRI of tumor: MRI with and without contrast should be obtained within [ADDRESS_427857], T2, FLAIR, and Diffusion weighted images. For recommended imaging 
protocol and sequence parameters, please see Appendix F . Images will be evaluated by [CONTACT_344521] . Images will be made 
available for central imaging review  
 All MRI processes for central radiology will be detailed in the 
study reference manual.  
•  
6.2.5 Day 8 ([ADDRESS_427858]- Surgery ± 3  days) 
• Performance status  
• Physical examination 
• ECG (Arm 2 and re- treatment arm only): An ECG will be obtained  at seven  days post-
surgery.  ECG recordings will be performed once the subject has been resting semi -
supi[INVESTIGATOR_344496] (with wait time of approximately 1 minute between recordings) . A 12- lead ECG 
recording will be performed in a standardized manner as outlined in the Study Refer ence 
Manual. Repeat measurements will be performed if any clinical abnormalities are observed or if artifacts are present.  
• Vital signs  
• Concurrent medications: continuous assessment  
• Adverse events: continuous assessment  
• Measurement of clinical chemistry parameters (Arm 2 and re- treatment arm  only) 
• Measurement of hematology parameters (Arm 2 and re- treatment arm  only) 
  
6.2.[ADDRESS_427859] -Surgery (±7 days) 
• Adverse events 
o Chart review and/or tel ephone contact [CONTACT_344522], , brain and spi[INVESTIGATOR_344497], toxicity 
assessment and disease status information.  
• Urine or serum p regnancy test (for females of childbearing potential) 
6.2.[ADDRESS_427860] -Surgery (±7 days ) and  [ADDRESS_427861] -Surgery (±7 days)  
• Adverse events 
o Monthly c hart review  and/or telephone contact [CONTACT_344523], , brain and spi[INVESTIGATOR_344497], 
toxicity assessment and disease status information . Any s ubject receiving 
additional therapy for their CNS tumor, including chemotherapy and/or radiation therapy within 3 months of surgery will be considered off study for safety 

Version Date: [ADDRESS_427862] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 63 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427863] begins additional tumor-
directed therapy . 
•  
  
 
6.[ADDRESS_427864] may be removed from protocol therapy after enrollment but prior to receiving study drug for any of the following reasons: 
• Withdrawal of consent for treatment 
• Subject is unable to receive study drug for any reason 
• Pregnancy 
The study may be terminated at any point in time at the discretion of the sponsor (See  Section 
11.3.6).  
6.4 Off Study Criteria  
Subjects will be considered Off Study for the following reasons: 
• Physician determines that study participation is not in subject’s best interest. 
• Study is terminated by [CONTACT_1034]. 
• Parent, subject, or guardian withdraws consent or assent  for continued participation. 
• Subject death. 
• Completion of protocol specific follow up period, three  months following surgery 
• Any subject receiving additional therapy for their CNS tumor, including chemotherapy and/or radiation therapy within three  months of surgery will be considered off study for 
safety observations at the time of starting additional therapy.  Safety data in th ese subjects 
will be included up to the time the subject begins additional tumor -directed therapy. Any 
on-going adverse events (AEs) at the time of off -study will be considered unresolved. 
 
The date and reason for the subject coming off study must be docum ented in the case report form.  
Subjects coming off study due to start of additional therapy are considered to have completed study as planned.   
 
 

Version Date: [ADDRESS_427865] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 64 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427866] (whether it is the experimental product o r the control) 
and which does not necessarily have a causal relationship with the investigational product. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Pre -existing events that increase in frequency or severity or change in nature 
during or as a consequence of use of a drug in human clinical trials, will also be considered as AEs. AEs may also include pre- or post -treatment  complications that occur as a result of 
protocol- mandated procedures (e.g., invasive procedures such as biopsies).  
For investigational medical devices, adverse events are any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including an abnormal laboratory finding) in subjects, users or other persons, whether or not related to the investigational medical device .  An adverse device ef fect is an adverse event related to the use of the investigational 
medical device.  It can include adverse events from insufficient or inadequate instructions for 
use, deployment, implantation, installation or operation, or any malfunction of the investigational device.  
Any medical condition or laboratory abnormality with an onset date before randomization is considered pre-existing and should be recorded on the medical history  CRF page(s).   
AEs will be collected from time of randomization through three  months after surgery  or until 
start of other tumor- directed therapy, whi chever is earlier . After the Day 8 visit, all subjects will 
be followed by [CONTACT_344524]/or telephone contact [CONTACT_344525], or until start of other tumor -directed therapy (chemotherapy, radiation 
therapy or other investigational therapy), whichever is sooner.  
If the patient experiences an AE considered to be  related  to study products , then the patient will 
be followed until resolution of that AE or until they are off study (whichever is earlier).  
An AE does not include: 
• Medical or surgical procedures (e.g., surgery, endoscopy, tooth extraction, transfusion); 
the condition that leads to the procedure is an AE 
• Pre-existing diseases or conditions present or detected prior to randomization that do not 
worsen  
• Situations where an untoward medical occurrence has not occurred (e.g., hospi[INVESTIGATOR_89783], social and/or convenience admissions)  
• Overdose of either study product or concomitant medication without any signs or 
symptoms unless the subject  is hospi[INVESTIGATOR_115913] 
7.[ADDRESS_427867], including 
the time and date of onset and resolution (where possible), severity, relationship to study product (tozuleristide, Canvas system , or both), relationship to neurosurgery, and outcome. 
Severity should be recorded and graded according to the CTCAE Version 5.0. In the absence of a specific toxicity grade, the following grading should be used: 
Version Date: [ADDRESS_427868] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 65 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427869] (tozuleristide, Canvas system , or both) and to neurosurgery 
should be assessed using the following definitions: 
1. Related: There is a reasonable causal relationship between study drug 
administration /device/procedure and the AE  
2. Not related: There is not a reasonable causal relationship between study drug administration/device/p rocedure and the AE  
The term "reasonable causal relationship" means there is evidence to suggest a causal relationship  
All AEs, regardless of severity, causality, or seriousness, will be reported from the date of randomization until three  months after surgery  or until start of tumor-directed therapy, whichever 
is earlier . After the Day 8 visit, all subjects will be followed by [CONTACT_22263]/or telephone 
contact [CONTACT_344526], or until an off-study 
criterio n is met, to collect survival, CSF cytology if clinically indicated, brain and spi[INVESTIGATOR_344497], 
toxicity assessment and disease status information.  
7.1.1 Serious Adverse Events 
A SAE is defined as follows:  
Any adverse drug or medical device experience that results in  any of the following outcomes: 
• Death  
• Life-threatening situation (subject is at immediate risk of death)  
• Inpatient hospi[INVESTIGATOR_344498]  
(excluding those for study therapy or placement of an indwelling catheter, unless associated with other serious events)  
• Persistent or significant disability/incapacity  
• Permanent impairment or a body structure or a body function  
• Congenital anomaly/birth defect in the offspring of a subject who received study product or led to fetal distress or fetal death  
• Other: Important medical events that may not result in death, be immediately life -
threatening, or require hospi[INVESTIGATOR_059], may be considered a SAE when, based upon appropriate medical judgment, they may jeopa rdize the subject and may require medical 
or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such events are:  
• Intensive treatment in an emergency room or at home for allergic bronchospasm 
Version Date: [ADDRESS_427870] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 66 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427871]  2021 • Resulted in medical or surgical intervention to prevent lif e threatening illness or 
injury or  permanent impairment to a body structure or a body function  
• Development of drug dependency or drug abuse 
[IP_ADDRESS]  Clarification of Serious Adverse Events  
Death is an outcome of an AE and not an AE in itself . 
All deaths  of subjects on study, regardless of cause, must be reported to Blaze Bioscience. 
“Life -threatening” means that the subject was at immediate risk of death from the event as it 
occurred. This does not include an event that might have led to death, if it had occurred with 
greater severity.  
Complications that occur during hospi[INVESTIGATOR_98176] . If a complication prolongs 
hospi[INVESTIGATOR_059], it is a SAE.  
The investigator should attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information . When available, a diagnosis should be documented as the AE 
and/or SAE and not the individual signs/symptoms. 
“In-patient hospi[INVESTIGATOR_059]” means the subject has been formally admitted to a hospi[INVESTIGATOR_344499], for any length of time. 
The following hospi[INVESTIGATOR_8609]: 
• A visit to the emergency room or other hospi[INVESTIGATOR_20347] <24 hours, that does not result 
in admission (unless considered an important medical or life- threatening event). 
• Hospi[INVESTIGATOR_307] a dmission for observation only does not constitute an SAE 
• Elective surgery, planned prior to signing consent 
• Admissions as per protocol for a planned medical/surgical procedure 
• Routine health assessment requiring admission for baseline/trending of health status (e.g., routine colonoscopy) 
• Medical/surgical admission other than to remedy ill health and planned prior to entry into the study. Appropriate documentation is required in these cases 
• Admission encountered for another life circumstance that carries no bearing on health status and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, caregiver respi[INVESTIGATOR_040], family circumstances, administrative reason)  
• Extended hospi[INVESTIGATOR_344500]  
 
7.1.[ADDRESS_427872] is  confirmed eligible and 
is thus enrolled  on the re -treatment arm .  
Version Date: [ADDRESS_427873] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 67 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427874]  2021 After the Day 8 visit, all subjects will be followed by [CONTACT_22263]/or telephone contact 
[CONTACT_344527], or until an off- study criterion is met, to collect survival, CSF 
cytology if clinically indicated, brain and spi[INVESTIGATOR_344497], toxicity assessment and disease status information . 
If the patient experiences an AE considered to be  related  to study products , then the patient will 
be followed until resolution of that AE or until the patient is off study (whichever is earlier). 
The Investigator will assign attribution of the possible association of the event with tozuleristide 
or the Canvas system  or both, or to neurosurgery, and this information will be entered into the 
appropriate case report form. The Investigator must also comply with all reporting requirements to their institutional Data and Safety Monitoring Committee and Institutional Review Board (IRB).  
7.3 SAEs and Expedited Reporting  
Blaze Bioscience has requirements for the expedited reporting of SAEs that meet specific criteria of the appropriate regulatory authorities; therefore, all appropriate parties must be notified as soon as possible and within 24 hours of the investigator becoming aware of the event. The procedures for reporting all SAEs, regardless of causal relationship, are as follows: 
• In the case of a SAE , information should be recorded on a SAE Report Form and faxed 
or emailed to the contacts below.  
• Initial SAE notification can be done by [CONTACT_344528] [ADDRESS_427875]’s CRF.  
An SAE may qualify for reporting to regulatory authorities if the SAE is considered to have a possible causal relationship to the study product and is unexpected/unlisted based upon the current Investig ator’s Brochure. In this case, all investigators will receive a formal notification 
describing the SAE. 
Where this is required by [CONTACT_31665], and in accordance with the local 
institutional policy, the investigator should notify (in writin g) the IRB of SAEs according to 
local guidelines.  
7.4 Toxicity Management 
7.4.1 Definitions  
The grading of AEs and abnormal laboratory values will be based on the guidelines provided in the CTCAE Version 5.0 . 

Version Date: [ADDRESS_427876] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 68 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427877] be obtained from the laboratory appointed to analyze study samples. All management is based on changes from this value.  
7.4.2 Guidance for Dose Modification or Discontinuation of Treatment  
Dosing will be stopped if suspected adverse drug reactions, changes in vital signs, or clinical laboratory results are observed , and these changes pose a significant health risk.  
If the patient experiences an AE considered to be related to study products , then the patient will 
be followed until resolution of that AE or until they are off study (whichever is earlier). 
7.4.[ADDRESS_427878], please refer 
to the current  Tozuleristide Investiga tor’s Brochure . 
Version Date: [ADDRESS_427879] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 69 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427880]  2021 8  SPECIAL STUDIES  
8.1  
 
 
 
 
 
 
8.2 Investigational Device Information  
Refer to S ection 5.2 for information of the Canvas system. Detailed information is also provided 
in the current Canvas I maging System Investigator’s Brochure . 
8.3  
 
 
 
 
 
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427881] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 70 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427882]  2021 9 EVALUATION CRITERIA  
9.1 Independent Safety Monitoring Committee (SMC) 
The SMC’s responsibilities are to:  
• Review the protocol and plans for data safety and monitoring; 
• Conduct regular interim and final evaluation of study safety including aggregate and 
individual subject data related to safety, data integrity, and overall conduct of the study; 
• Consider factors external to the study when relevant information becomes available, such 
as scientific or therapeutic developments that may have an impact on participant safety, 
scientific integrity, or the ethics of conducting the study; 
• Protect the safet y of the study subjects;  
• Review and evaluate ad hoc safety issues concerning the study at the request of Blaze Bioscience; 
• Make recommendations to Blaze Bioscience concerning continuation, termination, or other 
modifications of the study based on the obser ved beneficial or adverse effects of the study; 
and 
• Operate according to the procedures described in the  charter and 
all procedures of the SMC.  
9.2 Central Radiology 
•  
 
•  
 
 
•  
 
 
• All MRI processes for central radiology are detailed in the study reference manual.  
9.3 Central Pathology 
• Primary tumor tissue specimens and equivocal tissue specimens will be required for 
central pathology assessment of presence or absence of tumor. Central pathology samples 
will be requested after completion of site final pathology report for standard clinical management.  “Other biopsy” tissue specimens, if obtained, will also be evaluated  by 
[CONTACT_193403]. 
• 
 
 

Version Date: [ADDRESS_427883] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 71 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427884]  2021 •  
  
• Central pathology will be blinded to treatment allocation and fluorescence data but will 
have access to routine pathology data (gross and microscopic pathology reports), images and/or slides for microscopic evaluation, and molecular/genetic data. 
•  
9.4  
 
 
 
 
 
 
 
 
 
9.5 Protocol Endpoint Assessment Committee (PEAC)  
The PEAC will monitor the progress of the study  
 
 
 
 
 
 
 
 
Enrollment will be halted once sufficient 
data (specimens and sub -groups) are available for analysis.  
 
 
   
Roles and responsibilities are outlined in the PEAC  study charter. 

Version Date: [ADDRESS_427885] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 72 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427886]  2021 10 STATISTICAL CONSIDER ATIONS  
10.1 Study Design/Endpoints  
The study design is presented in Section 3. 
 
. 
10.1.1 Primary Endpoints  
The primary efficacy endpoints are: 
1. Ratio of sensitivity of tozuleristide fluorescence in equivocal tissue biopsies from 
subjects with fluorescence-positive tumors compared to the sensitivity of surgical designation from  the same biopsies under white light conditions 
2. Ratio of specificity of tozuleristide fluorescence in equivocal tissue biopsies from subjects with fluorescence-positive tumors compared to the specificity of surgical designation from the same biopsies under white light conditions  
3. Sensitivity of tozuleristide fluorescence to detect tumor in equivocal tissue biopsies from subjects with fluorescence-positive tumor 
4. Specificity of tozuleristide fluorescence to detect tumor in equivocal tissue biopsies from subjec ts with fluorescence-positive tumor 
 
 
   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427887] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 73 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427888]  2021 10.1.2 Secondary Endpoints  
The secondary efficacy endpoints are: 
1.  
 
 
2.  
 
 
 
 
 
 
 
Study endpoints related to the safety objective: 
1. All reported adverse eve nts (AEs)  will be graded according to the National Cancer 
Institute’s Common Terminology for Adverse Events (NCI CTCAE, Version 5.0) 
2. SAEs  
3. AE attribution of relatedness to tozuleristide  and/or Canvas system (related vs. 
unrelated).  
4. Laboratory parameters  
5. ECG parameters  
6. Vital signs  
 
 
 
 
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427889] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 74 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427890]  2021 •  
 
 
 
 
 
 
 
 
 
10.1.[ADDRESS_427891] deviation, median, and range (minimum, 
maximum) for continuous variables , and f requencies and percentages f or categorical variables.  
Statistical tests will be performed at either a one -sided significance level of 2.5% or a two-sided 

Version Date: [ADDRESS_427892] 2021  BB-006 (PNOC012)  
Confidential Page 75 of 95 BB-006 (PNOC012)  
Versi on Date: [ADDRESS_427893]  2021 significance level of 5%. All confidence intervals (CIs) will be constructed at a two -sided 95% 
confidence level.  
In addition, data collected after re -treatment will be listed and will not be included in the efficacy 
and safety analyses.  
10.2.1  
 
 
  
10.2.2  Analysis Pop ulations 
The full analysis popul ation ( FAP) for ef f icacy an alyses will c onsist of  all subjects who  
1.me
et all eligibility criteria
2. undergo neurosurgery and

Version Date: [ADDRESS_427894] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 76 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427895] neurosurgery on study.   
Study subjects in the full analysis population will be classified into four treatment groups: 
• Group 1 (Arm 1): subjects who do not receive tozuleristide , regardless of fluorescence 
outcomes and tumor diagnosis 
• Group 2 (Arm 2 Fluorescent): subjects who receive tozuleristide, have at least one 
fluorescence -positive study  tissue specimens of any type (primary, equivocal and other) 
based on imaging operator fluorescence assessment , and the subject’s central pathology 
consensus diagnosis is tumor, ambiguous, or not definitive 
• 
 
  
 
 
A subject is evaluable for efficacy if the subject meets the three criteria of the FAP  
 
   
The safety analysis population will consist of all subjects who receive any amount of tozuleristide or receive neuro surgery prior to any re -treatment . Safety data collected in the re -
treatment portion of the study will be listed separately.   
 
 
 
10.2.[ADDRESS_427896] disposition w ill be tabulated by [CONTACT_2939]. The number of subjects 
in each analysis population will be summarized by [CONTACT_2939] . Subjects who withdraw from 
the study prematurely will be summarized. The reason(s) for study discontinuation will be summarized. The number of subjects who do not undergo surgery will also be summarized by [CONTACT_2939] . 
10.2.[ADDRESS_427897] Characteristics  
Demographic and other baseline characteristics will be summarized with descriptive statistics by 
[CONTACT_2939] . 
10.2.5 Analyses of Primary Efficacy Endpoints  
The primary efficacy analyses will be based on Group 2 in the full analysis population (Section 10.2.2). The four sets of statistical hypotheses will be evaluated by [CONTACT_344529] -primary endpoints. 

Version Date: [ADDRESS_427898] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 77 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427899] Exposure  
The dose of tozuleristide administrated in volume (mL) and am ount (mg) will be summarized  
 

Version Date: [ADDRESS_427900] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 78 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427901]  2021 10.2.8 Safety Analyses 
All safety summaries will be tabulated for subjects who receive tozuleristide and subjects who 
do not receive tozuleristide in the safety population.  Safety data collected  in the re -treatment 
portion of the study will be listed separately . 
[IP_ADDRESS]  Adverse Events  
Adverse events will be coded using MedDRA 21.0. Adverse events will be defined as treatment-emergent if they are newly occurring or worsen following surgery (Arm 1) or treatment with 
tozuleristide (Arm 2  and re -treatment ). Adverse events will be scored for severity using NCI 
CTCAE version 5.0 if applicable, or the protocol specified severity stated in Section 7.1 . 
All adverse events (AEs)  and SAEs collected during the study will be  graded according to the 
National Cancer Institute’s Common Terminology for Adverse Events (NCI CTCAE, Version 
5.0) along with attribution  of relatedness to tozuleristide and/or Canvas system  and neurosurgery 
(related vs. unrelate d). 
Treatment -emergent AEs, SAEs, severity of AEs, tozuleristide- related AEs, Canvas- related AEs, 
neurosurgical- related AEs, and AEs leading to withdrawal from study will be summarized by 
[CONTACT_167500]. In the event of multiple occurrences of the same AE with the same preferred term in the same subject, the AE will be counted once at the greatest severity/relatedness.  
[IP_ADDRESS]  Clinical Laborator y Parameters, ECG and Vital Signs 
Laboratory parameters will be summarized with descriptive statistics of the change from baseline value by [CONTACT_7206]. For laboratory parameters defined in CTCAE, shifts of baseline grade to the worse post -baseline grade will also be presented. Subject laboratory values will be listed with 
toxicity grades and out- of-range flags.  
ECG parameters, including QT and QTcF will be summarized with descriptive statistics per time 
point.  Changes from baseline for individual QT/QTcF will be reported as both absolute values (e.g., >450 ms) and relative changes (e.g., > 30 ms).   If available, out of range ECG parameters will be assessed for the presence of genetic factors that could contribute to the abnormal ECG findings.  ECG data wi ll also be analyzed as a function of pharmacokinetic exposure measures.  
10.2.9  
 
 
 
 
10.2.10  
 

Version Date: [ADDRESS_427902] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 79 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427903]  2021 10.2.11  
 
 
 
10.2.12 Interim Analysis  
Interim analysis is not planned.  
 
 
10.3 Sample Size  
Approximately 114 subjects are planned for tre atment  in this study. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 

Version Date: [ADDRESS_427904] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 80 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427905]  2021  
 
    
10.4 Stratification Factors  
The randomization procedure will not be stratified.  Permuted block randomization will be used. 

Version Date: [ADDRESS_427906] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 81 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427907]  2021 11 DATA REPORTING / REGULATORY REQUIREMENTS  
11.1 Data Reporting 
11.1.1 Method  
The investigator will ensure that this study is conducted in full conformance with the protocol, 
the “Declaration of Helsinki” prior to [ADDRESS_427908]’s participation in the clinical study. Assent, when appropriate, will be obtained according to institutional guidelines. 
The investigator must utilize an IRB -approved consent form for documenting written informed 
consent. The original signed and dated informed consent for m must  be retained in accordance 
with institutional policy, and a copy of the signed consent form must  be provided to the subject 
or legally acceptable representative.  
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. 
These documents should be classified into two separate categories:  
• Investigator’s Site File (ISF), an d 
• Subject clinical source documents 
The ISF will contain the protocol/amen dments, CRFs, query forms, IRB approval with 
correspondence, informed consent, drug records, staff curriculum vitae, and authorization forms, 
and other appropriate documents and correspondence. 
Subject clinical source documents include subject hospi[INVESTIGATOR_307]/cli nic records, physician’s and nurse’s 
notes, appointment books, original laboratory reports, ECG, electroencephalogram, X-ray, MRI, 
pathology and special assessment reports, and consultant letters. All clinical study documents, including documents created or modiﬁed in electronic format, must be retained by [CONTACT_344530] [ADDRESS_427909] approval of a marketing application in an ICH region ([LOCATION_003], Europe, or Japan) and until there are no pending or contemplated marketing applications in an ICH region; or if no application is filed or if the application is not approved for such indication, until two years after 
the investigation is discontinued and regulatory authorities have been notified. The investigator must notify Blaze Bioscience, prior to destroying any clinical study records. 
Should the investigator wish to assign the study records to another party or move them to another 
location, Blaze Bioscience must be notified in advance.  
If the investigator cannot guarantee this archiving requirement at the study site for any or all of the documents, special arrangements must be made between the investigator and Blaze Bioscience to store these in a sealed container(s) offsite so that they can be returned to the 
Version Date: [ADDRESS_427910] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 82 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427911] show the identification and quantity of each unit disposed of, the method of destruction (taking into account the requirements of local law), and the person who disposed of the test substance. Such records shall be submitted to the Sponsor. 
  
  
 
 
 
 
 
 
 
 
 
 
11.[ADDRESS_427912] be obtained before starting the study and should be 
documented in a letter to the investigator specifying the protocol number and version and the date on which the IRB met and granted the approval. 
Any modifications made to the protocol and/or informed consent form after receipt of IRB 
approval must also be submitted by [CONTACT_344531]. 
11.3.[ADDRESS_427913] operating procedures (SOPs) of Blaze Bioscience and/or its representatives or designees, GCP, and applicable regulatory requirement(s).  
Authorized representatives of Blaze Bioscience, its designee, a regulatory authority, or the IRB may visit the center to perform audits or inspections. The investigator should contact [CONTACT_344532] a regulatory agency about an inspection at their 

Version Date: [ADDRESS_427914] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 83 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427915]  2021 center.   If an a udit or inspection occurs, the i nvestigator and institution agree to allow the 
auditor/in spector direct access to all relevant documents and allocate their time and the time of 
their staff to the auditor/inspector to discuss findings and any relevant issues.  
11.3.3 Training  
Study teams at the clinical sites will be trained on all aspects of the study . 
Training will be conducted at the study initiation visits with the study coordinators, pharmacists, 
and investigators as well as at a central investigator meeting and in pre- scheduled webinars.  
The study teams will be trained on the protocol evaluations, safety reporting, investigator brochure, 
informed consent, CRFs, pharmacy procedures, dosing, receipt and storage of tozuleristide,  
, inclusion and exclusion criteria, study manual, investigator responsibilities, 
GCP,   and data en try into the clinical database.  
Every site’s imaging operators and neurosurgeons will also receive specialized training in 
operating the Canvas system and image acquisition and interpretation including the following: 
• Instructions on specimen flow in the Operating room and labeling of imaged specimens 
•  
• Operation of the Canvas system  including pi[INVESTIGATOR_344501] 
•  
• Assessment of fluorescence i ntraoperatively 
• Image and video capture and storage of data 
 
 
11.3.[ADDRESS_427916] access to the investigator’s source documentation in order to verify the data recorded in the CRFs for consistency.  
The study monitor, as a Blaze Bioscience representative, will contact [CONTACT_344533]/she will be allowed, on request, to inspect the various records of the trial (CRFs and other pertinent data) provided that subject confidentiality is maintained in accord with local requirements.  
It will be the monitor’s responsibility to monitor the CRFs at regular intervals throughout the study, to verify the adherence to the protocol and the completeness, consistency, and accuracy of the data being entered on them. The investigator agrees to allow the monitor direct access to all relevant documents and to allocate his/her time and the time of his/her staff to the monitor to discuss findings and any relevant issues.  
11.3.[ADDRESS_427917] be awaited before significant changes can be 

Version Date: [ADDRESS_427918] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 84 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427919]  2021 implemented  except when necessary to eliminate immediate hazards to patients; i. e., if the risk 
benefit ratio is affected and/or the modification represents a change in basic trial definitions such 
as objectives, design, and sample size or outcome measures.  
In the event of a SAE or AE, the investigator may institute any medical procedures deemed appropriate. Administrative changes to the protocol are defined as minor corrections and/or clarifications that have no effect on the way the study is to be conducted or on the safety of the subjects. These administrative changes will be agreed  upon by [CONTACT_344534].  
11.3.6 Conditions for Terminating the Study  
The study may be prematurely terminated by [CONTACT_344535]/risk becomes unfavorable for continuation of the study. Additionally, Blaze Bioscience reserves the right to terminate the study at any time on the basis of new information regarding safety or efficacy, or if study progress is unsatisfactory, or for other administrative or commercial reasons.  
 
Should this be necessary, the procedures will be arranged on an individual study basis after 
review and consultation by [CONTACT_14381]. In terminating th e study, Blaze Bioscience and the 
investigators will ensure that adequate consideration is given to the protection of the subjects’ 
interests. The investigator should promptly inform the subjects and ensure appropriate therapy and follow-up and inform the relevant regulatory authorities and the IRB. All delivered study materials must be collected and all CRFs completed to the extent possible.  
11.3.[ADDRESS_427920] assure the subjects’ anonymity will be maintained and that their identities are protected from unauthorized parties. On CRFs or other documents submitted to the Sponsor, subjects should not be identified by [CONTACT_2249], but by [CONTACT_423]’s initials and an identification code. The investigator should keep a subject identification log showing codes, names, and addresses. Documents not for submission to Blaze Bioscience (e.g., subject’s written consent forms, identification log), should be maintained by [CONTACT_1210]. 
All information concerning the study treatment and the Sponsor Company and its operation, such 
as patent applications, formulae, manufacturing processes, basic scientific data, and material not previously published are considered confidential and shall remain the sole property of the Sponsor. The investigator agrees to use this information only in accomplishing the study and will not use it for any other purposes without written consent from the Sponsor. 
11.3.[ADDRESS_427921] editorial and ethical practice, Blaze Bioscience will support publication 
of the data from this study. 
 
 
 
 
 

Version Date: [ADDRESS_427922] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 85 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427923]  2021  
  
  
 
  
 
 
 

Version Date: [ADDRESS_427924] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 86 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427925]  2021 REFERENCES  
1. Barbagallo GM, Certo F, Heiss K, Albanese V. 5 -ALA fluorescence-assisted surgery in pediatric 
brain tumors: report of three  cases and review of the literature. Br J Neurosurg.  2014 
Dec;28(6):750-4.  
2. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 
2010;362(10):865-869.  
3. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing  Patient-
Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA 
2017;318(2):197-198.  
4. Beez T, Sarikaya-Seiwert S, Steiger HJ, Hänggi D. Fluorescence-guided surgery with 5-
aminolevulinic acid for resection of brain tumors in children--a technical report. Acta Neurochir 
(Wien).  2014 Mar;156(3):597-604.  
5. Brinkman, Tara M., et al. Long-Term Neurocognitive Functioning and Social Attainment in 
Adult Survivors of Pediatric CNS Tumors: Results From the  St Jude Lifetime Cohort Study. 
Journal of Clinical Oncology . 2016;34(23): 1358– 1367.  
6. Bull KS, et al. Child -Related Characteristics Predicting Subsequent Health -Related Quality of 
Life in 8 - to 14 -Year -Old Children with and without C erebellar Tumors: a Prospective 
Longitudinal Study. Neuro -Oncology Practice. Nov 2014;1(3):114 –122. 
7. Chi SN , Zimmerman MA , Yao X, Cohen KJ , Burger P , Biegel JA, Rorke-Adams LB , Fisher MJ, 
Janss A, Mazewski C , Goldman S , Manley PE , Bowers DC , Bendel A , Rubin J , Turner CD, 
Marcus KJ, Goumnerova L , Ullrich NJ, Kieran MW . Intensive multimodality treatment for 
children with newly diagnosed CNS atypi[INVESTIGATOR_186681]. J Clin Oncol.  2009 
Jan20;27(3):385-9.  
8. Deshane J, Garner CC, Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem . 2003;278(6): 4135- 4144.  
9. Duckworth J, Nayiager T, Pullenayegum E, et al. Health -related quality of life in long -term 
survivors of brai n tumors in childhood and adolescence: A serial study spanning a decade. J 
Pediatr Hematol Oncol . 2015;37(5):362– 367. 
10. Fisher PG, Tihan T, Goldthwaite PT, Wharam MD, Carson BS, Weingart JD, Repka MX, Cohen KJ, Burger PC. Outcome analysis of childhood low -grade astrocytomas.  Pediatr Blood Cancer.  
2008 Aug;51(2):245- 50. 
11. Gajjar A, Packer RJ, Foreman NK, Cohen K, Haas- Kogan D, Merchant TE; COG Brain Tumor 
Committee. Ch ildren's Oncology Group's 2013 Blueprint for Research: Central Nervous System 
Tumors. Pediatr Blood Cancer . 2013;60(6):1022-6.  
12. Gurney, JG, et al. Social Outcomes in the Childhood Cancer Survivor Study Cohort. Journal of Clinical Oncology . Oct 2009;27(14): 2390 –2395. 
13. Hervey -Jumper SL, Berger MS. Role of surgical resection in low- and high-grade gliomas. Curr 
Treat Options Neurol . 2015 Apr;16(4):284.  
14. Huang T, Mueller S, Rutkowski MJ, Han SJ, Bloch O, Barani IJ, Parsa AT, Chang SM. 
Multidisciplinary care of patients with brain tumors. Surg Oncol Clin N Am . 2013;22(2):161-78.  
15. Jakacki RI, Burger PC, Kocak M , Boyett JM , Goldwein J, Mehta M , Packer RJ , T
 arbell NJ, 
Pollack IF. Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: a report from the Children's Oncology Group. Pediatr Blood Cancer.  2015 May;62(5):776- 83. 
16. Kirch R, Reaman G, Feudtner C, Wiener L, Schwartz LA, Sung L, et al. Advancing a 
comprehensive cancer care agenda for children and their families: institute of Medicine 
Workshop highlights and next steps. CA Cancer J Clin. 2016;66(5):398 –407. 
17. Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient -
reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled t rials. J Clin Oncol.  
2014;32(14):1480- 1501.  
Version Date: [ADDRESS_427926] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 87 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427927]  2021 18. Kesavan K, Ratliff J, Johnson EW , et al. Annexin A2 is a molecular target for TM601, a peptide 
with tumor -targeting and anti -angiogenic effects. J Biol Chem . 2010;285(7):4366–74.  
19. Kuhlthau KA , et al. Prospective Study of Health -Related Quality of Life for Children With Brain 
Tumors Treated With Proton Radiotherapy. Journal of Clinical Oncology . Oct 
2012;30(17):2079 –2086.  
20. Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL, Janosky J, Deutsch M. 
Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery . 1995;37(4):655-57.  
21. Robertson PL. Advances in treatment of pediatric brain tumors. NeuroRx . 2006;3(2):276-91.  
22. Rogers L, Pueschel J, Spetzler R, Shapi[INVESTIGATOR_2152] W, Coons S, Tho mas T, Speiser B. Is gross-total 
resection sufficient treatment for posterior fossa ependymomas? J Neurosurg. 2005 Apr 102(4): 
629-36.  
23. Schulte F, Russell KB, Cullen P, Embry L, Fay -Mcclymont T , et al. Systematic review and meta-
analysis of health -related quality of life in pediatric CNS tumor surv ivors. Pediatric Blood & 
Cancer. 2017;64(8) . 
24. Sievert AJ, Fisher MJ. Pediatric low -grade gliomas. J Child Neurol . 2009;24(11):1397- 408. 
25. Stroud MR, Hansen SJ, Olson JM. In vivo bio-imaging using chlorotoxin- based co njugates. Curr 
Pharm Des. 2011;17:4362 –71. 
26. Stummer W , Pi[INVESTIGATOR_115112] U , Meinel T , Wiestler OD, Zanella F , Reulen HJ; ALA- Glioma Study 
Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol.  2006 May;7(5):392 -
401. 
27. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belan ger K, Brandes 
AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, 
Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research 
and Treatment of Cancer Brain Tumor and Radiotherapy Groups.; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.  N Engl J Med. 2005 Mar 10;352(10):987-96.  
28. Tabori U, Laberge AM, Elle zam B, Carret AS. Cancer Predisposition in Children with Brain 
Tumors. In: Scheinemann K., Bouffet E. (eds) Pediatric Neuro -oncology . 2015;69 -89. 
29. U.S. Cancer Statistics Working Group. [LOCATION_002] Cancer Statistics: 1999 –2012 Incidence and 
Mortality Web -based Report. Atlanta: U.S. Department of Health and Human Services, Centers 
for Disease Control and Prevention and National Cancer Institute; 2015 . Available at: 
www.cdc.gov/uscs . 
30. US DHHS, FDA. Guidance for industry: patient -reported outcome measures: use in medical 
product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006; 4:79.  
31. Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, et al. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res.  
2007;67(14):6882 –8. 
32. Yang T, Temkin N, Barber J, Geyer JR, Leary S, Browd S, Ojemann JG, Ellenbogen RG. Gross total resection correlates with long -term survival in pediatric patients with glioblastoma. World 
Neurosurg. 2013 Mar -Apr;79(3-4):537- 44. 
33. Zeltzer PM , Boyett JM , Finlay JL , Albright AL , Rorke LB, Milstein JM , Allen JC , Stevens 
KR, Stanley P, Li H, Wisoff JH, Geyer JR , McGuire- Cullen P, Stehbens JA, Shurin SB , Packer 
RJ. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for 
medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.  J Clin Oncol.  1999 Mar;17(3):832-45.  
34. Zhao  S, Wu J , Wang C , Liu H , Dong X , Shi C , Shi C , Liu Y , Teng L , Han D, Chen X , Yang G, 
Wang L , Shen C , Li H. Intraoperative fluorescence-guided resection of hi gh-grade malignant 
gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta- analysis 
of prospective studies.  PLoS One.  2013 May 28;8(5):e63682.  
Version Date: [ADDRESS_427928] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 88 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427929]  2021 APPENDIX A: PERFORMANCE STATUS CRITERIA  
Karnofsky  Lansky 
Score  Description  Score  Description  
100 Normal, no complaints, no evidence 
of disease  100 Fully active, normal.  
90 Able to carry on normal activity, 
minor signs or symptoms of disease. 90 Minor restrictions in physically strenuous 
activity.  
80 Normal activity with effort; some  
signs or symptoms of disease.  [ADDRESS_427930] of his/her needs.  60 Up and around, but minimal active play; 
keeps busy with quieter activities.  
50 Requires considerable assistance and 
frequent medical care.  50 Gets dressed, but lies around much of the 
day; no active play, able to part icipate in 
all quiet play and activities.  
40 Disabled, requires special care and assistance.  40 Mostly in bed; participates in quiet activities.  
30 Severely disabled, hospi[INVESTIGATOR_374].  Death not imminent. 30 In bed; needs assistance even for quiet play. 
20 Very sick, hospi[INVESTIGATOR_374].  
Death not imminent. 20 Often sleepi[INVESTIGATOR_007]; play entirely limited to 
very passive activities.  
10 Moribund, fatal processes 
progressing rapi[INVESTIGATOR_375].  10 No play; does not get out of bed. 
 
 
 
  
  
Version Date: [ADDRESS_427931] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 89 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427932]  2021  
 
 
 
  

Version Date: [ADDRESS_427933] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 90 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427934]  2021  
 
 
 

Version Date: [ADDRESS_427935] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 91 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427936]  2021  
 
 
  
 
   
 
   
 
   
 
 
  
  
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
   
 
   
 
 
 
  
 
   
  
  
 
 
  
 
    
  
 
 
  
 
  
  
  
 
 
 
 
 
   
 
 
  
  
 

Version Date: [ADDRESS_427937] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 92 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427938]  2021  

Version Date: [ADDRESS_427939] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 93 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427940]  2021   
 
 
  
  
   
     
  
 
  
 
   
  
 
  
 
   
   
  
    
   
  
   
 
   
 
  
 
   
 
   
 
  
 
   
 
  
  
    
 
   
  
   
 
 
  

Version Date: [ADDRESS_427941] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 94 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427942]  2021  
 
  
  
   
    
  
 
  
 
  
 
  
  
 
  
 
  
 
  
  
 
   
 
  
 
   
  
 
   
 
  
 
  
  
 
  
 
  
  
 
  
  
  
 
   
 
  
 
  
  
 
 
 
   
 
  
 
  
 
 
     
     
     
     
     
 
 

Version Date: [ADDRESS_427943] 2021  
 BB-006 (PNOC012)  
 
Confidential Page 95 of 95 BB-006 (PNOC012)  
 Version Date: [ADDRESS_427944]  2021  
 
    
   
 
   
 
  
  
  
  
 
 
 
 
 
  
    
    
 
 
        
 
 
        
        
 
 
        
 
    
  
  
        
  
        
     
    
 
  
        
 
    
  
  
 
        
  
 
    
    
 
 
        
 
 
        
              
     
    
    
 
 
 
 
 
 
 
 
 
 
